Bronchiolitis — The Wheezing Infant and the Case for Doing Less

Audience
Parents of infants 2–12 months
Target length
~1,400 words
Status
Draft v1 (translated from Japanese v1)
Original
../232_bronchiolitis.md

Lead

A baby a few months old breathing with a wheezing, whistling sound. For a parent hearing it for the first time, that sound is deeply alarming. This is the hallmark presentation of bronchiolitis — responsible for approximately 100,000 hospitalizations of children under one year in the United States annually [1], and one of the most significant respiratory illnesses of infancy. What makes this disease unusual is the existence of a formal, evidence-based list of things not to do. Understanding the standard of care helps parents observe symptoms at home with more accuracy and make better decisions about when to seek help.


What Is Bronchiolitis?

is an inflammatory disease of the lower airways (bronchioles) affecting primarily children under two years of age. Inflammation causes the mucous membranes to swell, secretions to increase, and the already narrow airways to become prone to obstruction. This is what produces the characteristic wheeze and respiratory distress.

accounts for 50–80% of cases, but rhinovirus, human metapneumovirus (hMPV), and parainfluenza virus can also be responsible [1]. Seasonal patterns track RSV closely, peaking in autumn and winter.

Bronchiolitis is not asthma. Asthma is a chronic condition driven by bronchial hypersensitivity and characterized by recurrence; bronchiolitis is an acute illness that follows a viral infection. That said, multiple prospective studies have shown some correlation between a history of severe bronchiolitis and later asthma risk — though whether this is a causal relationship remains unclear [5].


The Course of Illness and Recognizing Severity

The first two to four days bring upper respiratory symptoms: runny nose, mild fever, cough. Wheeze and respiratory difficulty typically peak around days two to three. The following observations are clinically useful for assessing whether hospitalization may be warranted:

Cyanosis — a blue or purple tint to the lips or fingernails — is a sign of high urgency.


The AAP Guideline's Case for Doing Less

The 2014 clinical practice guideline on bronchiolitis issued by the American Academy of Pediatrics (AAP) drew attention not for what it recommended, but for what it explicitly ruled out [1].

The following interventions are not recommended for mild-to-moderate bronchiolitis, whether in inpatient or outpatient settings:

This represents the outcome of an evidence-based reassessment: treatments that had been widely practiced simply failed to prove their effect.


What Supportive Care Actually Looks Like

The interventions with established benefit are straightforward:

For hospitalized infants, supplemental oxygen is provided as needed. Tube feeding or intravenous fluids are added when oral intake is insufficient. High-flow nasal cannula oxygen therapy is sometimes used when respiratory distress is marked.


Translating Evidence into Everyday Decisions


Summary

The great majority of bronchiolitis cases resolve spontaneously over one to two weeks. Supportive care is the mainstay of management; antibiotics, bronchodilators, and corticosteroids are not recommended for mild-to-moderate illness. What appears to be "doing nothing" is, in fact, the evidence-based choice. The decision to hospitalize should rest on respiratory rate, SpO₂, and feeding adequacy — not on the volume or character of the wheeze alone.


References

  1. Ralston SL, Lieberthal AS, Meissner HC, et al.; American Academy of Pediatrics. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014;134(5):e1474–e1502. doi:10.1542/peds.2014-2742. PMID: 25349312.
  2. Smyth RL, Openshaw PJ. Bronchiolitis. Lancet. 2006;368(9532):312–322. doi:10.1016/S0140-6736(06)69077-6. PMID: 16860703.
  3. Schuh S, Freedman S, Coates A, et al. Effect of oximetry on hospitalization in bronchiolitis: a randomized clinical trial. JAMA. 2014;312(7):712–718. doi:10.1001/jama.2014.8637. PMID: 25138334.
  4. Hartling L, Bialy LM, Vandermeer B, et al. Epinephrine for bronchiolitis. Cochrane Database Syst Rev. 2011;(6):CD003123. doi:10.1002/14651858.CD003123.pub3. PMID: 21678340.
  5. Sigurs N, Gustafsson PM, Bjarnason R, et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med. 2005;171(2):137–141. doi:10.1164/rccm.200406-730OC. PMID: 15503826.